Two dozen researchers from the Fred Hutchinson/University of Washington Cancer Consortium received first-ever Team Science awards from the International Society for Biological Therapy of Cancer on Oct. 3 at the organization’s 25th annual meeting in Washington, D.C.
The Consortium team, led by Drs. Phil Greenberg and Mac Cheever of the Clinical Research Division and the late Dr. Alex Fefer, was one of six groups recognized globally for their major contributions to research and clinical translation of cancer immunotherapy and biological therapy.
“This team has helped foment and lead an ongoing revolution to demonstrate the feasibility and develop the enormous potential of T-cell-based immunotherapies to treat and cure cancer, even in advanced stages,” said iSBTc President Dr. Bernard Fox at the ceremony. “These scientists have achieved significant success in T-cell therapy, vaccine therapy, novel agents that augment T-cell immunity, and hematopoietic cell transplantation as T-cell-mediated immunotherapy.”
The 24 researchers honored included Drs. Cassian Yee, Hootie Warren, Joseph Blattman and Stan Riddell, all of the Clinical Research Division.
The iSBTc is comprised of clinicians, researchers, students, postdoctoral fellows and allied health professionals dedicated to improving cancer treatment outcomes by advancing the development and application of biological therapy/immunotherapy through interaction, innovation, translation and leadership.
[Adapted from an iSBTc news release]
Every dollar counts. Please support lifesaving research today.